Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

0.8912
-0.0688-7.17%
Post-market: 0.90200.0108+1.21%19:55 EDT
Volume:791.86K
Turnover:742.32K
Market Cap:84.75M
PE:-4.60
High:0.9876
Open:0.9800
Low:0.8900
Close:0.9600
52wk High:2.05
52wk Low:0.5501
Shares:95.09M
Float Shares:85.42M
Volume Ratio:2.06
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1936
EPS(LYR):-0.3228
ROE:-83.76%
ROA:-78.18%
PB:2.57
PE(LYR):-2.76

Loading ...

Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812

TIPRANKS
·
Sep 29

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (Ct1812) in DLB

Reuters
·
Sep 29

Cognition Therapeutics - Meeting to Align on Primary Endpoint for Zervimesine Phase 3 Dlb Study

THOMSON REUTERS
·
Sep 29

Cognition Therapeutics - Schedules Type C FDA Meeting for October 20, 2026

THOMSON REUTERS
·
Sep 29

Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Sep 22

Amazon - Cognition and AWS Sign Multi-Year Strategic Collaboration Agreement

THOMSON REUTERS
·
Sep 15

Cognition Therapeutics CEO Lisa Ricciardi Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Soligenix Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 07

Cognition Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)

TIPRANKS
·
Aug 07

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Benzinga Earnings
·
Aug 07

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

THOMSON REUTERS
·
Aug 07

Cognition Therapeutics Q2 Income from Operations USD -7.738 Million

THOMSON REUTERS
·
Aug 07

Cognition Therapeutics Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth?

Simply Wall St.
·
Jul 16

Cognition Therapeutics Posts Press Release on B. Riley Summit Fireside Chat to IR Website

Reuters
·
Jul 13

H.C. Wainwright Keeps Their Buy Rating on Cognition Therapeutics (CGTX)

TIPRANKS
·
Jun 25

Cognition Therapeutics gets FDA feedback on zervimesine study

TIPRANKS
·
Jun 24

Cognition Therapeutics Targets Mid-2027 Start for Phase 3 Zervimesine Trial in DLB Psychosis

Reuters
·
Jun 24

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (ct1812) in Dlb Psychosis Following Receipt of FDA Meeting Minutes

THOMSON REUTERS
·
Jun 24